Raf kinases are essential for regulating cell proliferation, survival and tumorigenesis. However, the mechanisms by which Raf is activated are still incompletely understood. Phosphorylation plays a critical role in Raf activation in response to mitogens. The present study characterizes phosphorylation of S338, a crucial event for Raf-1 activation. Here we report that mutation of K375 to M diminishes phosphorylation of S338 on both wild type Raf-1 in cells treated with EGF/TPA and a constitutively active mutant in which Y340Y341 are replaced by two aspartic acids, a conserved substitution present in natural B-Raf. The loss of S338 phosphorylation in these Raf mutants is not engendered by a mutation-induced conformational change, inasmuch as mutation of another site (S471 to A) in the activation segment also abolishes S338 phosphorylation, whereas both the kinase dead mutants of Raf-1 are phosphorylated well by active Pak1.
Abstract.
Raf kinases are essential for regulating cell proliferation, survival and tumorigenesis. However, the mechanisms by which Raf is activated are still incompletely understood. Phosphorylation plays a critical role in Raf activation in response to mitogens. The present study characterizes phosphorylation of S338, a crucial event for Raf-1 activation. Here we report that mutation of K375 to M diminishes phosphorylation of S338 on both wild type Raf-1 in cells treated with EGF/TPA and a constitutively active mutant in which Y340Y341 are replaced by two aspartic acids, a conserved substitution present in natural B-Raf. The loss of S338 phosphorylation in these Raf mutants is not engendered by a mutation-induced conformational change, inasmuch as mutation of another site (S471 to A) in the activation segment also abolishes S338 phosphorylation, whereas both the kinase dead mutants of Raf-1 are phosphorylated well by active Pak1.
Furthermore, our data demonstrate that EGF-stimulated phosphorylation of S338 is inhibited by Sorafenib, a Raf kinase inhibitor, but not by the MEK inhibitor U0126. Interestingly, a kinase dead mutation and Sorafenib also markedly reduces phosphorylation of S445 on B-Raf, a site equivalent to Raf-1 S338. Finally, our data reveal that S338 is phoshorylated on inactive Raf-1 by an active mutant of Raf-1 when they are dimerized in cells and that artificial dimerization of Raf-1 causes S338 phosphorylation, accompanied by activation of Erk1/2. Altogether, our data suggest that S338 on Raf-1 is autophosphorylated in response to mitogens.
Introduction.
Raf family of serine/threonine protein kinases consists of three isoforms, A-Raf, B-Raf and Raf-1 (C-Raf), all of which serve as immediate downstream effectors of Ras (1) . In response to extracellular stimuli, activated Ras-GTP relays signals to Raf, which in turn evokes a serine/threonine phosphorylation cascade through sequential phosphorylation of MEK1/2, ERK1/2 and further downstream effectors to elicit a variety of cellular responses.
Raf-1 is ubiquitously expressed in mammalian cells, while A-Raf and BRaf exhibit more tissue-specific expression profiles (2) . Likewise, knocking out individual genes for these Raf isoforms creates different phenotypes (3) . Deletion of the Raf-1 gene in an inbred background causes death of mice in midgestation, and its knock-out in an outbred strain results in general growth retardation, developmental abnormalities and death shortly after birth (4) (5) (6) . Similarly, deletion of the B-Raf gene is embryonic lethal due to defects in neuroepithelial differentiation and maturation and in the maintenance of endothelial cells (7) . Elimination of A-Raf causes intestinal and neurological defects, but the pups are born alive (8) .
Activating ras mutations are found in 30% of all human cancers (9) . In some cancers such as breast cancer, even if Ras is not mutated, amplification of growth factor receptors (e.g. EGFR), or alterations in other positive or negative regulators of Ras also lead to higher than normal levels of Ras activity (10) . As a result, the Raf/MEK/ERK pathway is constitutively activated, leading to increased cell proliferation and invasion. The B-Raf mutants have been frequently identified, whereas oncogenic mutations for Raf-1 and A-Raf have not yet been reported in human cancers (11, 12) .
Activation of Raf-1 has served as a framework for the other two isoforms, but still remains incompletely understood. Raf-1 activity is tightly controlled by both intramolecular and extramolecular interactions. In the resting state, S259 on Raf-1 is phosphorylated and bound by 14-3-3, which possibly promotes the intramolecular interaction between the aminoterminal regulatory domain and the carboxyterminal kinase domain, preventing the spontaneous association of Raf-1 with Ras-GTP and thus keeping it inactive (13, 14) . When cells are provoked by mitogenic ligands, Ras-GTP binds to a site aminoterminally proximate to the 14-3-3 binding site, thereby destabilizing the interaction between 14-3-3 and the phospho-S259 site and allowing its dephosphorylation by protein phosphatase 2A (15) (16) (17) (18) . Unlike phospho-S259, 14-3-3 binding to phospho-S621 is absolutely required for Raf kinase activity (19) (20) (21) (22) . Removal of 14-3-3 from Raf-1 greatly inhibits Raf kinase activity, and this inhibition can be relieved by adding bacterially expressed recombinant 14-3-3 (22) . These studies strongly suggest that 14-3-3 acts primarily to maintain the active conformation of Raf-1.
In response to mitogens, phosphorylation occurs in both the aminoterminal and the carboxyterminal regions.
For instance, phosphorylation of both S338 and Y341 that is located in the junction region between the aminoterminal negative domain and the carboxyterminal kinase domain (23) (24) (25) (26) (27) (28) (29) . The Src family has been implicated in the phosphorylation of Y340 (in insect Sf9 cells) and Y341 (in mammalian cells) (23, 24, (27) (28) (29) . Interestingly, phosphorylation of Y341 is barely detectable unless vSrc is coexpressed with Raf-1. Nevertheless, like S338, substitution of Y341 with alanine or phenylalanine abolishes Raf-1 activation, whereas its mutation to aspartic acid increases Raf kinase activity. Phosphorylation of S338 and Y341 dissociates the intramolecular interaction (30) (31) (32) (33) and the extramolecular interaction of Raf-1 with RKIP (34) .
The p21-activated protein kinases (Pak), mammalian homologues of yeast Ste20-like serine/threonine protein kinases, are activated by direct binding of Rac and Cdc42 GTPases (35) . Members of the Pak family appear to mediate cross-talk between Ras/Raf/MEK and Rac/Cdc42 (36) (37) (38) (39) (40) . However, it is controversial as to if Pak is a bona fide S338 kinase mediating growth factors to activate Raf-1 (28) .
We have demonstrated that activation of Cdc42/Rac/Pak by the microtubule depolymerizing drug nocodazole results in S338 phosphorylation and activation of Raf-1, independent of Ras (41) . In contrast, the Cdc42/Rac/Pak module does not mediate EGFinduced activation of Raf-1 (41) . Therefore, a true kinase phosphorylating S338 during the course of growth factor-induced Raf-1 activation still remains elusive.
A number of studies have shown that phosphorylation of S471, T491, S494, S497 and S499(42-44) occurs during Raf-1 activation. These phosphorylation sites are located between subdomains VII and VIII (activation segment) in the Raf-1 catalytic domain.
The biological importance of their phosphorylation is supported by the isolation at a high frequency from human cancers of a B-Raf oncogene containing the activating mutations V599D or V599E (12, (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) . The valine exists in all three Raf isoforms, next to the phosphorylation site in the activation segment (e.g. T598V599 in B-Raf, T491V492 in Raf-1) (44, 56) . Chong et al (44) have shown that phosphorylation of T491 and S494 is involved in the activation of Raf-1. In addition, S497 and S499 are phosphorylated by PKC (42,43). Mutation of these double sites partially blocks Raf activation by TPA, but it doesn't affect growth factor-induced activation (57, 58) .
To search for an additional kinase that phosphorylates S338 in response to growth factors, we first asked if this site is autophosphorylated. Thus, we mutated lysine 375 to methionine (K375M) at the ATP binding site of the catalytic domain of Raf-1 and examined S338 phosphorylation state. To our surprise, the effect of EGF/TPA on S338 phosphorylation was severely impaired by this kinase dead mutation. The inhibition might not be attributed to conformational changes, as the ability of this mutant to be phosphorylated by Pak1 was as great as that of the wild type Raf-1. A second mutant converting S471 to A in the activation segment behaved the same as the K375M mutant. Interestingly, when the equivalent lysine in B-Raf (K482) or Raf-1 340D/341D (K375), a constitutively active mutant of Raf-1, was changed to methionine, S445 and S338 phosphorylation was also diminished. Furthermore, phosphorylation of these two sites was inhibited by Sarofenib, a Raf inhibitor. Therefore, our results suggest that S338 on Raf-1 is autophosphorylated in response to EGF or TPA. In addition, our results demonstrate that dimerization plays a role in phosphorylation of Raf-1 at S338.
Experimental Procedures
Materials-Phorbol 12,13-dibutyrate (TPA) was purchased from Sigma. EGF and U0126 were from Calbiochem. The anti-Myc monoclonal antibody 9E10.2 was purchased from American Tissue Culture Collection.
The anti-GST monoclonal antibody, anti-Raf E10 monoclonal antibody and anti-Raf C12 polyclonal antibody were from Santa Cruz. Phospho-MEK, phospho-ERK1/2 and their non-phosphorylated forms were from Cell Signaling Technology. Glutathione (GSH) sepharose was purchased from GE Healthcare Life sciences. The rat monoclonal antibody against Raf-1 phospho-S338 was from Millipore. The Anti-EE epitope antibody was a gift from Dr. A. Makkinje.
Sorafenib was purchased from LC Laboratories. The dimerization drug AP1510 was provided by ARIAD Pharmaceuticals, Inc.
Plasmid DNA and site-directed mutagenesis
Plasmid DNA for Myc-Raf, GST-Raf, FKBP12-Myc-Raf, Pak1, MEK1, and Ras were used as we previously described zluo et al nature (41) . K to M mutation on B-Raf and S621 to A mutation were made using Quick Change Kit manufactured by Stratagene. Other Raf mutants tagged by flag epitope were constructed in pCMV5. Transfections, Immunoprecipitation and Western blot -Human embryonic kidney 293 cells (HEK293T) were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum. Transfection of plasmid DNA was carried out using the calcium phosphate precipitation method (41) . The Pak1 siRNA sequence was selected using the Dhamacon program (sense: UGUCUGAUGAGGAGAUCUUdTdT). Double stranded RNA oligonucleotides were synthesized by Dhamacon and transfected with oligofectamine according to the protocol provided by the manufacture (Invitrogen). Forty-eight hours posttransfection, cells were serum-starved in DMEM containing 0.1% fetal bovine serum for 16-20 h, treated with TPA or EGF for 15 min and then lysed in a lysis buffer (25 mM Tris-HCl, pH 7.8, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM Na 3 VO 4 and 25 mM β-glycerol-phosphate, 1 mM DTT, 1% NP-40 and protease inhibitors) (41) . Cell debris was removed by centrifugation at 14,000 × g at 4°C for 15 min and protein concentrations in cell lysates were measured using Bio-Rad Protein Assay kit.
For Western blotting, cell extracts were separated by 8% SDS-PAGE and electrophoretically transferred to Immobilon (Millipore).
The membranes were blocked, incubated with specific antibodies and then with a HRP-conjugated second antibody. Immunoreactive bands were visualized by the enhanced chemiluminescence (ECL) detection system.
For immunoprecipitation, proteins of interests were first normalized by Western blotting. Cell lysates containing equal amount of specific proteins were then incubated with protein A/G agarose (Santa Cruz Biotechnology) preabsorbed with specific antibodies at 4°C overnight. The precipitates were washed, as described before (41) .
For purification of recombinant GST-Raf, the lysates were incubated with GSH beads and washed as immunoprecipitation. Raf-1 Kinase Assay -Raf-1 kinase activity was measured by a coupled enzyme assay in which bacterially expressed recombinant GST-MEK1 and a kinase dead mutant of ERK2 were sequentially added to the Raf preparation in the presence of [γ-32 P]ATP (100 μM, 4000 cpm/pmole), as described previously. The reaction was stopped by the addition of a SDS-PAGE sample buffer, and the labeled mixture was resolved by 8% SDS-PAGE, transferred to Immobilon and visualized by autoradiography. The radiolabeled ERK2 bands were excised and quantified by liquid scintillation counting.
Results

EGF-induced activation of Raf-1 is independent of Pak1
To ascertain if Pak kinases are the bona fide enzymes that phosphorylate S338 in response to mitogens, we transfected siRNA for Pak1 into HEK293T cells and then examined the effects of EGF on phosphorylation of Raf-1, MEK1/2, and ERK1/2.
The results revealed that phosphorylation of Raf at S338 and MEK at S218/S222, sites phosphorylated by active Raf, as well as ERK phosphorylation, was not affected. In contrast, phosphorylation of MEK at S298, a specific site phosphorylated by Pak1 (59, 60) , was diminished by Pak1 siRNA ( Figure 1A ). Next, we made a series of mutations to mimic or disable phosphorylation in two sets of sites, S338-Y341, the negative region between the aminoterminal regulatory and carboxyl kinase domains, and S471S494 in the activation segment and tested the impacts of phosphorylation of these sites on Raf kinase activity. We transfected these mutants into HEK293T cells and carried out an in vitro kinase assay. As shown in Figure 1B , mutation of Y340Y340 to DD gave rise to the greatest activation of Raf-1, concurrently with a dramatic increase in S338 phosphorylation. Secondarily, T491S494 to ED conversion also significantly increased kinase activity. In contrast, mutation of S338S to A brought down the kinase activity of the Raf-1 491E494D mutant to a basal level. Likewise, mutation of T491S494 to AA also greatly diminished the activity of Raf 340D341D, regardless of residual phosphorylation of S338. These results suggest that phosphorylation of both groups are necessary for Raf activation.
Different effects of kinase-dead mutations of Raf1on EGF-induced and Pak1-mediated S338 phosphorylation
To determine if S338 phosphorylation requires an intact kinase domain structure, we transfected a kinase dead mutant, K375M, and wild type Raf expressed as a GST fusion protein into HEK293T cells and examined S338 phosphorylation in response to EGF or TPA. As shown in Figure 2A , S338 phosphorylation was markedly impeded by the K375 to M mutation. The failure of S338 to be phosphorylated might be accounted for by several reasons; for example, the mutation may disturb the tertial structure of Raf-1, so as to interfere with its phosphorylation by an upstream kinase; secondly, the site is possibly phosphorylated by downstream kinase and thirdly, it is autophosphorylated.
To test these possibilities, we first transfected GST-Raf-1, full length or carboxyl kinase domain, into HEK293T cells with or without an active Pak mutant, and examined S338 phosphorylation. As shown in Figure 2B , both the wild type and KM mutant Raf were equally phosphorylated at S338 by Pak1. In parallel, we used another mutant, S471A, a site further downstream away from S338 as compared to K375. The mutation of S471 to A has been shown to abolish Raf kinase activity (61) . Our result revealed that phosphorylation of S338 on this mutant was also impeded in response to TPA and EGF ( Figure 3A, B) . Conversely, when an active mutant of Pak1 was cotransfected with the S471A mutant ( Figure 3A ), S338 was phosphorylated as potently as it was on the wild type Raf-1. Finally, our data showed that mutation of W342 to A completely abrogated S338 phosphorylation induced by both active Pak1, TPA and EGF ( Figure 3C, D) , suggesting that this residue is required for S338 phosphorylation under both scenarios.
In addition, we tested if S338 phosphorylation was attributed to downstream kinases. Thus, HEK293T cells were starved and treated with or without the MEK inhibitor U0126 or the Raf inhibitor Sarofenib prior to incubation with EGF. Using anti-phospho-S338 antibody, we could detect phosphorylation of both Raf-1 and BRaf ( Figure 4A ). While S338 phosphorylation was stimulated by EGF, phosphorylation of S445, an equivalent site, was constitutive, consistent with previous findings (27, 32) . Interestingly, we found that while U0126 did not affect EGFstimulated S338 phosphorylation on Raf-1 or constitutive phosphorylation of S445 on B-Raf, Sarofenib greatly impaired phosphorylation of both ( Figure 4) . These results suggest that S338 or S445 is not phosphorylated by MEK1/2 or ERK1/2, downstream of Raf, but might be autophosphorylated.
To further test if S338 on Raf-1 and S445 on B-Raf are autophosphorylated, we mutated K375 to M on Raf-1 340D/341D and K482 to M on B-Raf and transfected them into HEK293T cells. As shown in Figure 5A , when the catalytic kinase domain containing the Y340D/Y341D substitution was expressed, S338 was highly phosphorylated in the absence of any treatment, which was several fold greater than that of wild type Raf-1 C activated by TPA. It was then significantly reduced by the K375 to M mutation. Of note, the phosphorylation signal was still equal to that of wild type Raf-1 induced by TPA. As compared to wild type B-Raf, phosphorylation of the KM mutant at S445 was markedly reduced ( Figure 5B ). The residual signal in both B-Raf KM and Raf C DD/KM is probably attributed to cross-reaction of the phospho-antibody to the two acidic residues or mutation renders them a better substrate for other upstream kinase such as Pak.
The effect of S621 phosphorylation on S338 phosphorylation
Binding of 14-3-3 to phospho-S621 is essential for Raf kinase activity toward MEK1. To test if S621 exerts a similar effect on S338 phosphorylation, we converted S621 to A in the context of Raf kinase domain, wild type or 340D/341D mutant, and transfected them into HEK293T cells. As shown in Figure  6A , TPA stimulated S338 phosphorylation equally well on both wild type and S621A mutant Raf-1. When Raf-1C 340D/341D was cotransfected with MEK1, it was almost fully active in terms of its ability to stimulate phosphorylation of ERK1/2 and bind to MEK1, whereas Raf-1C 340D/341D/621A was inactive and unable to bind MEK1 ( Figure  6B ). Interestingly, phosphorylation of S338 was nearly the same in both Raf-1C variants. Thus, the result distinguishes the structural requirement for MEK kinase activity and S338 kinase activity and also indicates that S338 phosphorylation is not sufficient for Raf activation.
The effect of Raf-1 dimerization on S338 phosphorylation
We and others have previously shown that Raf-1 exist as homodimer or heterodimer with B-Raf that promotes their activation (62, 63) . We then evaluated if the dimerization played a role in the regulation of S338 phosphorylation.
In this regard, we cotransfected GST-Raf-1, wild type and the KM mutant with Flag-Raf-1 340D/341D at different doses and purified Raf complexes by GSH sepharose beads. Figure 7A shows that phoshorylation of S338 on both Raf variants increased as more Raf 340D/341D bound, despite that the KM mutant showed less phosphorylation than the wild type. Next, we coexpressed GSTRaf-1, wild type (WT) or K375M mutant (KM) with Flag-Raf-1, WT, KM, or 340D/341D mutant and sequentially purified GST-Raf-1 and FlagRaf-1 after treatment of the cells with or without EGF. Our results showed different degrees of S338 phosphorylation of GST-Raf-1, depending on the combination of Flag-Raf-1 ( Figure 7B ). The greatest phosphorylation was observed on GST-Raf-1 when it was coexpressed with wild type Flag-Raf-1 in the cells treated with EGF or on the KM GST-Raf-1 coexpressed with the FlagRaf-1 340D/341D mutant.
Then the phosphorylation decreased on GST-Raf-1 KM when cotransfected with wild type and the KM Flag-Raf-1. Again, we observed the dimerization of these two versions of Raf-1. When the copurified Flag-Raf was assayed on S338 phosphorylation, most were barely detectible except that high amount of phosphorylation was found on the Flag-Raf 340D341D mutant Obviously, this difference is due to the fact that a small portion of Flag-Raf-1 was pulled down by GST-Raf-1 and that the specific activity of S338 phosphorylation on the DD mutant was much greater than that of the wild type Raf-1. When S338 phosphorylation was examined on flag immunoprecipitates, we observed that S338 phosphorylation on wild type Raf was suppressed by coexpression of the kinase-dead mutant (lower panel of Figure 7B ).
Finally, we transfected FKBP12-Myc-Raf-1 into HEK293T cells and incubated the cells with the dimerization drug AP1510 that induces the dimerization of FKBP12. Figure 7C shows that S338 phosphorylation was progressively enhanced, as doses of the drug were increased In keeping with this, Erk phosphorylation was also increased, although the effect of the drug was not as potent as that of EGF. Collectively, these results suggest that dimerization stimulates S338 phosphorylation on Raf-1.
Discussion
In the present study, we have shown that mutation of K375, essential for ATP binding site, to M, and S471 to A in the activation segment both abolish S338 phosphorylation of Raf-1 in response to EGF or TPA, whereas these mutants are still phosphorylated well by Pak1. Likewise, mutation of K482 to M on B-Raf and K375 to M on the Raf-1 340D/341D mutant diminishes phosphorylation of S445 and S338, respectively. The phosphorylation is also suppressed by treating the cells with the Raf inhibitor Sarofenib. Thus, these results suggest that S338 is autophosphorylated during the course of Raf-1 activation induced by mitogens such as EGF and TPA, while S445 is autophosphorylated in B-Raf to maintain its high basal activity. Our results show that S621, the carboxyl 14-3-3 binding site, is necessary for MEK kinase activity of Raf-1, but dispensable for S338 phosphorylation. Finally, our data indicate that dimerization of Raf-1 plays a role in S338 phosphorylation. Therefore, the present study provides novel insights into the mechanism of S338 phosphorylation of Raf-1 Phosphorylation has been known to play an important role in Raf activation after Ras-GTP binding. In the past, tremendous efforts have been made to determine the phosphorylation sites and to identify the responsible kinases. The crucial phosphorylation sites for Raf activation in response to growth factors include S338/Y341 and T491/S494 and S471 (64) . The kinases responsible for their phosphorylation still remain elusive.
Pak family has been shown to regulate the ERK pathway via phosphorylating MEK1 at S298 (59, 60, 65, 66) and Raf-1 at S338 (36) (37) (38) (39) (40) . While some of previous studies have demonstrated that Pak phosphorylation of MEK1 S298 promotes the ability of Raf-1 to phosphorylate and activate MEK1/2 (59,60), others do not observe a significant effect of S298 phosphorylation on MEK1 activation by growth factors when Pak1 expression is silenced or S298 is mutated to A (65, 67) . In consistent with these latter findings, the present study shows that knockdown of Pak1 by siRNA does not affect the ability of EGF to stimulate MEK phosphorylation at S218/S222 and ERK activation, while it diminishes phosphorylation of MEK1 at the Pak site S298 under the same condition.
One possible explanation is that although suppression of Pak1 expression may reduce MEK1 activation, it does not affect MEK2 (59) . The latter may be sufficient to offset the effect of reduced MEK1 activation.
Our studies and those of others (36-40) have shown that Pak1/2 can phosphorylate S338 under some circumstances, but they do not participate in growth factor-invoked S338 phosphorylation and activation of Raf-1. To test if this site is autophoshorylated in response to growth factor, we created two kinase dead mutants (K375M and S471A) of Raf-1 and assessed phosphorylation of S338. Our results showed that the mutation abolished the phosphorylation induced by EGF and TPA. This could be accounted for by several reasons. Using the specific MEK inhibitor U0126, we ruled out that it is not phosphorylated by MEK or ERK downstream of Raf-1. This is also not due to disturbance of the tertial structure of Raf-1 caused by the mutation, as the mutants are phosphorylated well by Pak1.
One could argue that overexpressed Pak might be promiscuous and it is not sensitive enough to discern the structural difference between wild type and mutant Raf-1. This argument is not supported by our observation that W342 to M mutation blocks S338 phosphorylation by Pak1. Interestingly, S445 on B-Raf, a site equivalent to Raf-1 S338, has been shown to be constitutively phosphorylated (27, 32) . In the present study, we mutated B-Raf K482 to M, equivalent to Raf-1 K375 to M mutation and found that the mutation markedly impaired S445 phosphorylation.
The same result was also observed with the mutation of K375 to M on Raf-1 340D/341D. Most strikingly, phosphorylation of S338 and S445 on endogenous Raf-1 and B-Raf, respectively, was greatly suppressed by the Raf inhibitor Sarofenib. Therefore, after excluding kinases downstream of Raf-1, our data suggest that S338 is autophosphorylated.
If S338 is autophosphorylated when Raf-1 is activated by mitogens such as EGF and TPA, the next question is how this is initiated. To address this, we tested a series of mutations and found that S338 phosphorylation appears to be independent of phosphorylation of T491S494 and S621. Zhu et al (61) have identified a new phosphorylation site, S471, responsive to EGF. When this site is converted to A or D, Raf-1 loses its activity, which is compensated by mutation of T491S494 to ED. This finding suggests that phosphorylation of S471 configures an active conformation, instead of creating an electrostatic effect of negative charge. It is possible to test if phosphorylation of S471 initiates S338 phosphorylation given that the S471 kinase has been identified. Another possible mechanism is that S338 phosphorylation is primed by phosphorylation of Y341. Mason et al (27) have described that when D447/D448 on B-Raf are replaced by two tryrosines, the level of S445 phosphorylation drops dramatically and it is restored by EGF, an event that is accompanied by changes in B-Raf kinase activity. Similarly to natural B-Raf, S338 is highly phosphorylated in the Raf 340D/341D mutant. Taken together, these results suggest that phosphorylation of S338 may ensue after that of Y341 during the course of Raf-1 activation by EGF.
Several lines of evidence suggest that dimerization plays a role in the regulation of Raf kinase activity.
First, we and others have previously shown that Raf-1 is invariably dimerized before and after EGF treatment and that artificial dimerization can induce Raf activation (62, 68) . Second, Ras has been reported to form a dimmer, which is required for the activation of Raf-1 (69) and third, it has recently been documented that Ras-stimulated heterodimerization between B-Raf and Raf-1 results in an increase in the latter's activity (70) . Intriguingly, Garnett et al (71) have shown that several B-Raf mutants isolated from human cancer cells do not display increased kinase activity per se, but they stimulate ERK activation and Raf-1 activity in vivo. Their results suggest that B-Raf via dimerizing with Raf-1 can stimulate phosphorylation and activation of the latter. In the same study, however, they do not find a significant increase in Raf-1 S338 phosphorylation when cotransfected with the B-Raf mutants. Our present study show that S338 phosphorylation of the kinase dead K375M mutant of Raf-1 is greatly suppressed, but not completely abolished in the cells treated with mitogens. The residual phosphorylation might be attributed to dimerization of the mutant with endogenous Raf-1. In addition, S338 phosphorylation is increased when the mutant is cotransfected with active Raf-1 340D/431D.
Thus, the results argue that homodimerization at least in part plays a role in mitogen-stimulated S338 phosphorylation. They also suggest different mechanisms by which heterodimerization and homodimerization regulates Raf-1 activation and phosphorylation.
Of note, when two versions of Raf were coexpressed and purified, we only observed a small amount of Raf associated with each other, instead of a stoichiometric level. The low level of association may suggest that the dimerization is mediated by a scaffold protein which is a limiting factor or that dissociation rate (Kd) is high. In keeping with this, we could not show a direct RafRaf interaction by the yeast two hybrid system or using purified Raf proteins (data not shown). By comparing the degree of 338 phosphorylation and kinase activity of the 340D/341D mutant with those of wild type Raf-1, we estimated majority of wild type Raf was not activated when cells were treated with EGF. This is in line with the general view that only 5-10% of Raf is activated by mitogens (64). It is not clear if only dimerized Raf can be activated by EGF or TPA. This question will be answered when the dimerization site is identified. Also, at this moment, we cannot exclude the possibility of cis-autophosphorylation.
Thus far, all existing data have documented that autophosphorylation of Raf exerts a negative effect on kinase activity (72) . In light of our results obtained in vivo, we propose that autophosphorylation could have both negative and positive effects on Raf kinase activity, probably depending on other factors involved such as timing. For example, the conclusion on the negative effect of autophosphorylation is based on the result of in vitro incubation of Raf with ATP after isolation of activated Raf-1. We believe that autophosphorylation of S338 is an early event during Raf-1 activation. One perplex is that we could not observe changes in S338 phosphorylation when Raf-1 is incubated in vitro with ATP. An explanation is that it requires an additional activating factor that might have been missed during the purification or phosphorylation of other sites such as Y341 or S471. This will be our next task in elucidating the mechanism of Raf activation.
Acknowledgements.
This work was supported by NIH grants: GM057959 and CA118918 (to Z.L.). We thank Dr. Kun-Liang Guan for providing us Raf and MEK constructs, Dr. A. Makkinje anti-EE antibody, and Dr. Guri Tzivion for constructive suggestions. We also thank ARIAD Pharmaceuticals, Inc. for the gift of the dimerization drug AP1510.
Abbreviations: ERK, extracellular regulated kinase; MEK, mitogen-activated protein kinase and extracellular regulated kinase kinase; EGF, epidermal growth factor; GSH, glutathione; GST, glutathione S-transferase; PAGE, polyacrylamide gel electrophoresis; PAK, p21-activated protein kinase; TPA, 4b-12-O-tetradecanoylphorbol-13-acetate; A. knockdown of Pak1 by siRNA suppresses EGF-stimulated phosphorylation of MEK1 S298, but not that of MEK S218/S222 or Raf-1 S338. The siRNA for human Pak1 or scrambled siRNA was transfected into HEK293T cells. Forty eight hours later, the cells were starved in 0.1% serum overnight prior to treatment with EGF (10 ng/ml) for 10 min. Cell lysates were prepared and blotted with antibodies against phospho-S298 MEK1, phospho-S218/S222 MEK1/2, total MEK1/2, phospho-ERK1/2, total ERK1/2, and Pak1, respectively. The lower part shows immunoblots for phospho-S338 and Raf-1 (E10) after immunoprecipitation of endogenous Raf-1. B. The effect of S338 phosphorylation on Raf kinase activity. Raf variants tagged with flag epitope, as indicated, were transfected into HEK293T cells. After two days, recombinant Raf was immunoprecipitated with the flag antibody and assayed for the in vitro kinase activity by sequential incubation with bacterially expressed and purified GST-MEK1 and kinase-dead Erk1. The autoradiogram shows 32 P-incorporated Erk1. Aliquots of Raf-1 IP were probed with anti-phospho-S338 and anti-flag antibodies, respectively. , 12h) , or U0126 (10 μM) for 30 min, and then treated with EGF for 10 min. Cell lysates were blotted with antibodies against phospho-S338, total Raf-1 (C12), total B-Raf, phospho-ERK1/2, and total ERK1/2, respectively. B. Since the suppression of S445 phosphorylation by Sarofenib was so obvious, the degree of suppression of Raf S338 phosphorylation was assessed by scan densitometry. Thus, anti-phospho-S338 signals in A were scanned and divided by the scan units of total Raf-1 signals and the ratio was expressed as fold of untreated cells. A. HEK293T cells were transfected with the catalytic domain variants of Raf-1, wild type and S621A and then stimulated with or without TPA. Recombinant Raf-1 purified by GSH pull-down was blotted with antiphospho-S338, phospho-S621 and GST, respectively. B. Raf-1 catalytic domain variants, wild type, 340D/341D or 340D/341D/621A, were transfected together with EE-tagged MEK1, purified, as described in A, and sequentially blotted with anti-EE, phospho-S338 and GST antibodies. Cell lysates were blotted with antibodies, as indicated. 
